Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SGHT
STRONG SELLSight Sciences, Inc. · Healthcare · United States · $267M · Avg Vol: $963K/d
COMPANY DESCRIPTION
Sight Sciences, Inc. is a medical device company dedicated to developing and commercializing innovative surgical and non-surgical solutions for prevalent eye diseases, primarily glaucoma and dry eye. The company leverages proprietary technologies like its OMNI Surgical System and TearCare System to address significant unmet needs, establishing a niche in the ophthalmology market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 71.3M | 81.1M | 79.9M | 77.4M | 2.7% | 79.6M | 86.0M | 95.7M | 11.2% |
| EPS | -2.36 | -1.80 | -1.14 | -1.03 | -0.74 | — | -0.70 | -0.76 | -0.66 | — |
| Shares | — | 48.3M | 49.1M | 50.9M | 53.5M | +10.8% | 54.4M | — | — | — |
| Debt | — | 35.0M | 35.4M | 40.4M | 40.8M | 5.2% | 41.8M | — | — | — |
| Equity | — | 160.1M | 120.2M | 87.5M | 63.9M | -26.4% | — | — | — | — |
| Op CF | — | -76.0M | -47.2M | -22.4M | -29.7M | — | -25.1M | — | — | — |
| Inv CF | — | -1.0M | -0.8M | -0.4M | -0.2M | — | — | — | — | — |
| Fin CF | — | 1.2M | 1.1M | 5.0M | 1.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SGHT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SGHT | Sight Sciences, Inc.(you) | $267M | 19 | STRONG SELL |
| TLSI | TriSalus Life Sciences, Inc. | $259M | 16 | STRONG SELL |
| CATX | Perspective Therapeutics, Inc. | $332M | 17 | STRONG SELL |
| CV | CapsoVision, Inc. | $324M | 16 | STRONG SELL |
| RXST | RxSight, Inc. | $215M | 22 | SELL |
| LAB | Standard BioTools Inc. | $326M | 22 | SELL |
| QTRX | Quanterix Corporation | $173M | 20 | STRONG SELL |
| IMR.AX | Imricor Medical Systems, Inc. | $455M | 16 | STRONG SELL |
| CLPT | ClearPoint Neuro, Inc. | $423M | 14 | STRONG SELL |
| TMCI | Treace Medical Concepts, Inc. | $259M | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.5%